Abstract:Spinal muscular atrophy (SMA) is a severe, debilitating neuromuscular condition characterised by loss of motor neurons and progressive muscle wasting. SMA is caused by a loss of expression of SMN1 that encodes the survival motor neuron (SMN) protein necessary for the survival of motor neurons. Restoration of SMN expression through increased inclusion of SMN2 exon 7 is known to ameliorate symptoms in SMA patients. As a consequence, regulation of pre-mRNA splicing of SMN2 could provide a potential molecular therapy for SMA. In this study, we explored if splice switching antisense oligonucleotides could redirect the splicing repressor hnRNPA1 to the hnRNPA1b isoform and restore SMN expression in fibroblasts from a type I SMA patient. Antisense oligonucleotides (AOs) were designed to promote exon 7b retention in the mature mRNA and induce the hnRNPA1b isoform. RT-PCR and western blot analysis were used to assess and monitor the efficiency of different AO combinations. A combination of AOs targeting multiple silencing motifs in hnRNPA1 pre-mRNA led to robust hnRNPA1b induction, which, in turn, significantly increased expression of full-length SMN (FL-SMN) protein. A combination of PMOs targeting the same motifs also strongly induced hnRNPA1b isoform, but surprisingly SMN2 exon 5 skipping was detected, and the PMO cocktail did not lead to a significant increase in expression of FL-SMN protein. We further performed RNA sequencing to assess the genome-wide effects of hnRNPA1b induction. Some 3244 genes were differentially expressed between the hnRNPA1b-induced and untreated SMA fibroblasts, which are functionally enriched in cell cycle and chromosome segregation processes. RT-PCR analysis demonstrated that expression of the master regulator of these enrichment pathways, MYBL2 and FOXM1B, were reduced in response to PMO treatment. These findings suggested that induction of hnRNPA1b can promote SMN protein expression, but not at sufficient levels to be clinically relevant.

A feedback loop regulates splicing of the spinal muscular atrophy-modifying gene, SMN2

Targeting SR proteins improves SMN expression in spinal muscular atrophy cells

A splicing silencer in SMN2 intron 6 is critical in spinal muscular atrophy

SMN Deficiency Causes Tissue-Specific Perturbations in the Repertoire of snRNAs and Widespread Defects in Splicing

A Splicing Silencer Insmn2intron 6 is Critical in Spinal Muscular Atrophy

Improvement of SMN2 pre-mRNA processing mediated by exon-specific U1 small nuclear RNA

Different Stability and Proteasome-Mediated Degradation Rate of SMN Protein Isoforms

Temporal and tissue-specific variability of SMN protein levels in mouse models of spinal muscular atrophy

Antisense Oligonucleotide Induction of the hnRNPA1b Isoform Affects Pre-mRNA Splicing of SMN2 in SMA Type I Fibroblasts

SAM68 is a physiological regulator of SMN2 splicing in spinal muscular atrophy

A spinal muscular atrophy modifier implicates the SMN protein in SNARE complex assembly at neuromuscular synapses

Pharmacokinetics, pharmacodynamics, and efficacy of a small-molecule SMN2 splicing modifier in mouse models of spinal muscular atrophy

A Positive Modifier of Spinal Muscular Atrophy in the SMN2 Gene.

Enhancement of SMN2 Exon 7 Inclusion by Antisense Oligonucleotides Targeting the Exon.

HnRNPR strongly represses splicing of a critical exon associated with spinal muscular atrophy through binding to an exonic AU-rich element

A super minigene with a short promoter and truncated introns recapitulates essential features of transcription and splicing regulation of the SMN1 and SMN2 genes

Rna-Sequencing Of A Mouse-Model Of Spinal Muscular Atrophy Reveals Tissue-Wide Changes In Splicing Of U12-Dependent Introns

Antisense Masking of an Hnrnp A1/A2 Intronic Splicing Silencer Corrects SMN2 Splicing in Transgenic Mice

NOVA1 Promotes SMN2 Exon 7 Splicing via Binding the UCAC Motif and Increases SMN Protein Expression

Targeting RNA-Splicing for SMA Treatment

A-44G transition in SMN2 intron 6 protects patients with spinal muscular atrophy